C
rohn's disease (CD) is a chronic relapsing disease that can occur in all segments of the gastrointestinal (GI) tract from the mouth to the anus. 1 At diagnosis, the inflammatory phenotype of the disease is predominant; however, more than 50% of patients with CD develop stricturing or penetrating complications within the first 10 years after diagnosis. 2 The natural history of CD may be influenced by the development of chronic transmural inflammation and associated fibrogenesis, which can culminate in intestinal stricture formation. 3 The clinical significance of stricturing CD is reflected by the severe symptoms of intestinal obstruction, frequent hospitalizations, and the fact that 75% of affected subjects have to undergo surgery in their lifetime. 4 Despite tremendous advances in the therapeutic armamentarium, including immunosuppressive drugs, the frequency of stricturing complications in CD has not significantly decreased over time. 5 Although immunosuppressants can delay the onset of complicated CD, they have not been shown to completely prevent it. 6 This therapeutic dilemma is further fueled by the fact that specific antifibrotic treatment options for stricturing CD are currently not available. 7 Symptomatic strictures significantly worsen the patients' quality of life and often lead to bowel obstruction, making surgical treatment approaches a frequently used option. 8 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
This however carries the risk of short bowel syndrome, loss of gut functionality, and high recurrence rates. 9, 10 Endoscopy-based therapeutic approaches seem to be a promising first-line alternative for treatment of fibrostenosing CD because they are minimally invasive and preserve intestinal length. 11 Indeed, the majority of CD-related strictures are located in the colon or ileocolon 12 and are thus accessible for through-the-scope systems using colonoscopy or balloon-assisted enteroscopy. [13] [14] [15] It has been reported that patients with short and isolated strictures without angulation are regarded as particularly suitable for endoscopic balloon dilation (EBD) therapy. 8, 11, 16 A significant amount of patients require a second EBD or surgical intervention after an initially successful EBD procedure. Despite these recommendations, the amount of high quality evidence is still limited. Most published studies are small and heterogenous making them hard to compare. The only available combined analysis carries several critical limitations. 16 Furthermore, accessory endoscopic techniques including local steroid injection, cutting procedures, and stent implantation have been proposed to improve the therapeutic outcome, but these approaches are often anecdotal and not validated.
We therefore analyzed all available EBD studies with .15 patients combined to elucidate technical feasibility, short-term and long-term efficacies as well as safety of EBD in stricturing patients with CD, and evaluate predictors for success. We additionally integrated the individual data from almost half of all included patients into a multivariate analysis.
MATERIALS AND METHODS

Literature Search and Data Selection
A formal systematic review with a comprehensive literature search was performed to assess all relevant citations found in Embase, MEDLINE (service of the US National Library of Medicine and the National Institutes of Health) and the Cochrane library for the following key words: ("Crohn's disease [CD]") OR "Crohn's" AND ("stricture" OR "endoscopic dilatation" OR "endoscopic dilation" OR "balloon dilation" OR "balloon dilatation"). In addition, references of cited original articles and reviews were further assessed for relevant publications. The search included studies between 1991 and 2013 and only included fulltext articles. All identified abstracts were dually assessed by D.B. and F.R. Only studies including patients with confirmed diagnosis of CD were included. All studies found in the literature containing at least 15 subjects were included into the analysis. The study by East et al 17 included 13 patients, but was still chosen because of its randomized controlled design and the use of steroid injections. A total of 33 studies were identified in the literature. 14, One of these was randomized. 26 Studies had between 13 and 178 subjects for a total of 1463 patients (Table 1) . A PRISMA diagram can be found in Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B408. Twelve studies containing less than 15 subjects each with a combined total of 87 subjects were excluded from the analysis.
All the corresponding authors of the respective papers were contacted through e-mail and the nonresponding investigators were recontacted up to 2 times. Twelve of the 31 authors provided their complete primary individual patient data for analysis, 14, 19, 27, 30, 32, 33, [35] [36] [37] 40, 45, 48 whereas 19 authors did not respond to our query. In total, data from 676 individual patients were evaluated, representing 46% of all published patients. These data represent the basis of the pooled individual patient analysis. The total number of individual patients and missing data per study can be found in Table 2 , Supplemental Digital Content 2, http://links.lww.com/IBD/B409. A one-step individual participant data approach was selected 49 because of its clinical and statistical advantages over aggregate meta-analysis alone. Ethical approval of this pooled analysis was not necessary because only published data were analyzed, and the individual patient data were provided in a deidentified fashion. Missing individual-level data were handled as described under Statistical analysis section.
The following definitions were used for the explored outcomes in the individual studies: (1) Technical success was mainly defined as the ability to pass a colonoscope through the nontraversable stricture after dilation 27, 30, 32, 33, 36, 37, 45 or correct stent placement. 40 The definitions for technical success as mentioned in the individual publications can be found in Table 3 , Supplemental Digital Content 3, http://links.lww.com/IBD/ B410. (2) Definitions for clinical efficacy included improvement of symptoms and no need for further endoscopic intervention, 36 relief of clinical symptoms of bowel obstruction during the following month after the endoscopic procedure, 30 remission of obstructive symptoms, 14 and disappearance of obstructive symptoms. 48 (3) Long-term success was defined as redilation-free period and intervention-free period, 27, 30, 48 no need for surgery, 32, 33, 35, 36 no need for new dilatation or surgery after first dilation, 37 absence of recurrent symptoms, 14, 45 and no symptoms at the end of follow-up or at least 1 year after stent implantation. 40 (4) Complications were defined as dilation-related perforation or fever, hematochezia, intense abdominal pain for 3 days, 19 bleeding, perforation, death 27 ; perforation, bleeding requiring blood transfusion, minor bleeding or abdominal pain or fever, 30 perforation, 14, 32, 33, 45, 48 abdominal pain, 33 bleeding with need for endoscopic re-intervention or blood transfusion 33 ; prolongation of the hospital stay or when they resulted in death or need for surgery within 1 week after dilation 37 ; stent migration 40 ; or hemorrhage and acute pancreatitis or hyperamylasemia. 48 (5) Need for surgery was defined as surgery at the site of the dilated stricture only. This excluded patients who had surgery in other areas of their intestine, e.g., a patient with a duodenal stricture undergoing ileocecal resection.
For the individual per-patient analysis, a protocol was developed and the following items were collected for all included subjects: stricture location, type and length of stricture, mode of dilation, endoscopic approach, maximum caliber of dilation, length of balloon, pressure of dilation, time of inflation, number of dilations, sedation, steroid injection, cutting techniques used, Table 3 , Supplemental Digital Content 3, http:// links.lww.com/IBD/B410, clinical efficacy (as defined by the individual investigators), major complications (bleeding, perforation, and dilation-related surgery), time to redilation, time to surgery, time to symptoms, active CD at the time of dilation, and follow-up time. Because the authors of this article did not have access to the individual patient charts, we used the definitions chosen by the authors of each study or provided by the investigators in the per-study and individual analysis and no patient was reclassified. No data on medications at the time of dilation or during follow-up were available.
Statistical Analysis
Study-level data were pooled using DerSimonian-Laird random effects model meta-analysis, and inverse variance weighting was used for pooling. In addition, the Clopper-Pearson method was used to estimate CIs. All studies (except 4, 13, and 27) provided median, range, or interquartile range for follow-up time; utilizing these values, a mean and standard deviation was estimated and these are the values that were pooled.
Individual patient data meta-analysis was performed using a one-step approach where data from all studies are modeled simultaneously and the regression accounts for correlations between subjects within a same study. Complete-case analysis was performed and studies that do not give a variable are excluded from analysis containing said variable.
Cox proportional hazards frailty models for clustered data were used to assess the factors associated with redilation, surgery, and symptoms during follow-up; correlations between events in the same cluster/study were modeled using a random component for the hazard function; the robust sandwich covariance matrix estimates to account for intracluster dependence. The proportionality of hazards assumptions was assessed by visual inspection of residual plots by time. Follow-up time for each event was defined as the time from dilation to either occurrence of event or last available follow-up if the event is not observed. Stricture location, de novo versus postsurgical stricture, maximal caliber of dilation, steroid injection, and use of concomitant techniques were considered for inclusion in all multivariable models because of their clinical importance. Length of stricture, active CD at the time of dilation, and time of inflation were also considered of clinical importance but were not included in the modeling process because of the high percentage of missing values (.30%). In addition, generalized linear mixed models with study as a random effect were used to assess associations between several factors and technical success, clinical efficacy, and major complications; Poisson distribution with a log link was used for a number of dilations, and binomial distribution with logit link was used for all the other outcomes. 50 A P , 0.05 was considered statistically significant. All analyses were performed using SAS (version 9.4; The SAS Institute, Cary, NC) or R (meta-package, version 3.2.1; The R Institute for Statistical Computing, Vienna, Austria).
RESULTS
In total, we identified 33 original studies in the literature that fit our inclusion criteria. The number of included patients varied from 13 to 178 with a mean value of 44 patients. 26, 36 The amount of performed dilatations being analyzed in single studies ranged from 15 to 767. 36, 38 Although all incorporated studies included at least 13 individuals, the 2 largest trials reported on 138 and 178 patients, respectively. 30, 37 One trial was conducted as a randomized controlled trial facilitating steroid injection 26 and a different one of the 33 studies contained a sham-treated or surgical control group. Table 1 presents descriptive statistics for each study as well as the random effects analysis and measures of variability.
Pooled Per-study Analysis
Within the 33 studies, a total of 1463 patients with CD were treated by 3213 EBD procedures for intestinal strictures (Table 1) . 97.9% of all interventions were performed under sedation, and the diameter of balloon used varied between 15 and 25 mm. 14, 30 98.6% of the intestinal strictures were located in the ileum and 62% of the analyzed strictures were anastomotic.
Technical success rate was 89.1% and EBD resulted in a relief of clinical symptoms (clinical efficacy) in 80.8% of all patients. Regarding the safety, major complications (defined as perforation, bleeding, or dilation-related need for surgery) occurred in 2.8% per procedure and in 6.2% per patient, considering the possibility of multiple dilations over time in the same study subject. During a median follow-up period of 36.6 months, 47.5% of patients reported symptomatic recurrence, whereas 28.6% of all patients had to undergo surgical intervention (Table 1 and Fig. 1 , Supplemental Digital Content 4, http://links.lww.com/ IBD/B411). It has to be mentioned, however, that these percent values represent raw percentages that are not corrected for the variable follow-up times within each individual study. In addition, to depict possible publication bias, we constructed the variability by effect size for each study in a funnel plot in Fig. 2 
Pooled Individual Patient Analysis
Primary data of 676 individual patients from 12 studies were available. The demographics of this population are depicted in Table 4 , Supplemental Digital Content 6, http://links.lww.com/ IBD/B413. We compared the subjects in which individual data were available with the subjects in whom only per study information was given and no clinically meaningful differences were detected (data not shown).
Most strictures were located in the ileum (81.5%) and were anastomotic strictures (58.3%) with a median length of 2 cm (25th percentile [P 25], 75th percentile [P 75]: 2.0, 4.0), suggesting comparability with the per study analysis data set in Table 1 .
Factors Associated with Short-term Dilation Outcome
We first evaluated factors associated with short-term dilation outcome. A greater maximum dilation diameter was found to be associated with a higher likelihood of technical success (OR 1.4, P , 0.001). De novo strictures were found to have a higher technical success rate compared with anastomotic strictures (OR 2.3, P , 0.001). However, clinical efficacy was neither associated with location or type of stricture nor dependent on maximal caliber of dilation. Stricture length was not associated with short-term dilation outcome (data not shown). The overall rates of symptom, intervention, and surgery-free survival in this cohort are depicted in Table 2 .
Factors Associated with Symptom Recurrence or the Need for Redilation
We next assessed predictive factors for symptom recurrence or the need for repetitive dilation therapy as long-term dilation outcome measures. There was no association between any of the 
Factors Associated with the Need for Surgery
Surgery could be considered the "hardest" endpoint for investigation of long-term dilation efficacy. As mentioned above, stricture length was neither associated with short-term dilation outcome nor need for redilation. In a multivariate analysis, however, testing for factors associated with a shorter time to surgery after EBD, every 1 cm increase of stricture length resulted in an increased hazard for surgery by 8% (P ¼ 0.005, Table 3 ).
Stricture location in the duodenum had an approximately 5 times increased hazard for shorter time to surgery compared with stricture location in the jejunum/ileum or colon (HR 4.7, P ¼ 0.038; HR 5.6, P ¼ 0.03; respectively). None of the other investigated factors, including type of stricture (Fig. 1) , active disease at the time of dilation, maximal balloon caliber, time of dilation, or accessory endoscopic therapies, was linked to need for earlier surgery.
Given the identification of stricture length as a risk factor, we further analyzed a cutoff value for surgery-free outcome. A stricture length of #5 cm was associated with a surgery-free outcome without (HR 2.4; 95% CI 1.3-4.2; P ¼ 0.003) and with (HR 2.5; 95% CI 1.4-4.4; P ¼ 0.002) correction for stricture location, type of strictures, balloon caliber, steroid injection, and accessory endoscopic therapy.
A cutoff for stricture length of #5 cm also showed a strong tendency to be associated with a redilation-free outcome (P ¼ 0.06, data not shown).
Factors Associated with the Occurrence of Complications After EBD
Finally, we analyzed factors influencing the occurrence of complications. A total of 11 patients experienced complications after EBD. None of the tested factors, including stricture location, type, length, disease activity, balloon caliber, length, and pressure were associated with complications.
DISCUSSION
We present a pooled analysis of 3213 EBD for CD-associated strictures in 1463 affected patients. In addition to a descriptive per study analysis, we generated a large database with individual-level data from 676 treated patients with CD as provided by the original investigators to identify predictive factors of beneficial short-term outcome, long-term efficacy, and complications.
We found an overall high technical and clinical efficacy with a robust long-term outcome and an acceptable complication rate. In a CD patient with intestinal obstruction on imaging and a stricture amendable to endoscopic therapy, we can relate that EBD will be successful in approximately 90% of cases, leading to symptoms improvement in 80% with a complication rate of 2.8%. In the next 24 months, there is a 73.5% chance for redilation and a 42.9% chance for need for surgical intervention. In other words, EBD was able to postpone a surgical intervention in close to twothirds of patients. We identified a higher balloon diameter as FIGURE 1. Risk of de novo versus anastomotic strictures for redilation, surgery, or symptomatic recurrence during follow-up. Evaluating the future course of de novo strictures (purple lines) and anastomotic strictures (red lines) after endoscopic dilation indicates that the risk for redilation, surgery, and symptomatic recurrence is comparable for both types of strictures during follow-up. a predictive factor for a higher technical success. There was no specific cutoff value for balloon size that could be recommended. De novo strictures showed a higher likelihood for technical success. The only long-term predictor for a surgery-free interval was the stricture length. Dilation of strictures #5 cm translated into a longer surgery-free survival time.
The presence of inflammation did not influence the shortterm or long-term outcomes and also did not have an effect on the complication rate. However, clinical judgment and caution are advised, as the presence of inflammation in the published studies was not graded in most investigations and we do not know if e.g., deeper ulcers or the most severe disease activity could lead to a higher rate of perforation.
An unresolved controversy is the dilation efficacy of naïve versus anastomotic strictures. We demonstrate that dilation of de novo strictures was associated with a higher technical success rate. Most importantly, there is no difference in long-term outcome after dilation of de novo or anastomotic strictures. This is in discrepancy to clinical practice, because IBD experts are more likely to attempt dilation of anastomotic compared with de novo strictures. 51 This perception, however, might be confounded by the generally shorter length of anastomotic strictures compared with de novo strictures, a factor that our analysis corrected for.
To our surprise, an increased caliber of dilation was associated with significantly higher rates of technical success, but did not result in increased rates of clinical efficacy and reduced need for redilation or surgery. In other words, increasing the balloon diameter only increased the short-term success, but did not improve symptoms or long-term outcome. Complication rates stayed the same independently of balloon diameter.
Two randomized controlled trials examined the endoscopic injection of corticosteroids into strictures post dilation. Although this approach was beneficial in a pediatric cohort (n ¼ 15 patients being treated with corticosteroid versus n ¼ 14 placebo treated 26 ), the outcome was worse after steroid injection in an adult population (n ¼ 7 being treated with corticosteroid versus n ¼ 6 placebo treated 17 ). We found no difference in short-term outcome, longterm outcome, or complication rate of strictures being treated with triamcinolone injection. We cannot exclude that predominantly severe strictures or recurrent strictures were selected to receive accessory endoscopic treatment with triamcinolone, which could influence the results. Nevertheless, our finding supports the viewpoint that steroid injection can currently not be recommended to accompany endoscopic dilation therapy until further data from randomized controlled studies are available. We detected a shorter time to redilation in patients in which accessory endoscopic therapies, such as infliximab injection, stent placement, or cutting techniques, were used, which did not hold true after correction for possible confounders. This also needs to be seen in lieu of reported major complications associated with e.g., endoscopic stent placement in more than 60% of patients. 52 Biodegradable stents seem to be advantageous, but data are still scarce. 53 Strictures can occur at any site along the GI tract, and although upper GI strictures are rare they are also amendable to EBD. 41, 48, 54 Our manuscript now provides guidance as of the long-term efficacy in this situation with EBD in the upper GI tract having an about 5-fold higher hazard for earlier surgery at the site of stricture compared with EBD in the small bowel or colon. This should be considered when educating our patients.
The most striking finding of this analysis was stricture length being the only predictive factor for long-term efficacy of EBD. Every cm increase in stricture length increased the hazard for early surgery by 8%. Based on our analysis, a stricture length cutoff for EBD of #5 cm can be recommended to maximize 55 and hence are not necessarily related to a reoccurrence of the stricture. Can EBD be performed repetitively on the same patient-an approach widely used by IBD specialists? 51 We cannot answer this question based on our data set, but published cohort studies 27, 37 suggest that short-term and long-term dilation efficacy and complication rates are the same compared with the first dilation. Hence, the decision about serial dilations versus surgery needs to be made between the physician and the patient, considering symptom burden and complication rates of both procedures.
Limitations
Although our study provides the highest level of evidence currently available in this area, the noncontrolled design of most studies may limit the reliability of the obtained results. Our study carries the inherent limitations of observational studies of intervention. This includes several reasons: (1) In the selected studies, heterogeneous definitions for outcomes, such as technical success, clinical efficacy, and complications were used. (2) Procedures were not performed according to a defined study protocol; therefore, interval between dilations, length of follow-up periods, accessory endoscopic therapies, or technical approach may vary even between patients analyzed in the same study. (3) In addition, patients may have received different medications e.g., immunosuppressive drugs, at the time of dilation, or during follow-up, which may per se have impact on the course of stricturing CD postdilation, information that we did not have available for our analysis. (4) The approach of the endoscopist may vary depending on the character of the stricture, and this might influence technical parameters and accessory endoscopic therapies and introduce a selection bias. (5) There are no uniform definitions for stricture, stenosis, and obstruction. (6) In addition, because of the heterogeneity of available studies, some factors including "inflammation at stricture" and "immunosuppressive medication" could not be assessed systematically. (7) Although the authors presume that most strictures were dilated in patients with symptomatic obstruction, some strictures might have been dilated in the absence of overt obstruction (preventative approach). A greater balloon diameter was associated with higher likelihood of technical success but not with improvement in symptoms. This observation may be confounded by stricture severity. Using greater balloon diameters may suggest that the stricture was not tight to begin with and hence it was easier to pass the scope, but the patient may have been asymptomatic. Thus, there is an urgent need for harmonization of definition as proposed previously, for example in case of the obstruction index suggested by the Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). 56 The optimal future approach would be controlled trials with patients included based on predefined criteria and being randomized before choosing different technical approaches or accessory endoscopic therapies. Until these data are available, we have to rely on single studies or combined analyses and our work is so far the largest and most detailed contribution to this.
In a previous combined analysis, 16 it has been reported that a stricture length of #4 cm could serve as a cutoff for surgery-free survival. Although this work led to an important advance in the field, it carries significant limitations. The included studies were not weighed based on their size. Hassan et al determined surgery as a risk factor during follow-up time for each study (as surgery yes/no), but time to surgery was not considered, a factor that we based our own analysis on. To illustrate the importance of this analytic difference, we used the statistical method used by Hassan et al in our larger data set (see Table 7 , Supplemental Digital Content 9, http://links.lww.com/IBD/B416) and were in fact not able to elucidate any risk factor for surgery. Finally, since the previously published combined analysis, multiple investigations were published and our combined data set increased the number of evaluated subjects from 347 to 1463, the number of individual patients from 167 to 676, and the number of analyzed dilations from 695 to 3213 allowing for sufficient power to detect or dispute risk factors for short-term or long-term efficacies as well as complications. It has to be noted that no death has ever been reported to be associated with EBD and even the most conservative surgical approach, in case of resection or strictureplasty, carries an increased risk of mortality. Can we prevent complications of EBD? Our combined analysis did not reveal any risk factors that could help guide us in this scenario.
Summary
EBD is a preferred alternative to surgery in patients with CD-associated strictures because of its high rate of short-term technical success and clinical success with substantial long-term efficacy and acceptable complication rates. Considering the limitations of this observational study of intervention, the main short-term predictor of technical success may be the use of a larger balloon diameter and de novo versus anastomotic stricture. Main long-term predictor of successful EBD may be a stricture length of #5 cm.
